Full Press Release Details
Recursion Announces First Patient Dosed In Phase 1 Clinical Study Of Rec 3565 A Selective Malt1 Inhibitor For Relapsed Or Refractory B Cell Lymphomas.
RXRX
Recursion Announces First Patient Dosed In Phase 1 Clinical Study Of Rec 3565 A Selective Malt1 Inhibitor For Relapsed Or Refractory B Cell Lymphomas
Key Takeaway: Recursion Announces First Patient Dosed In Phase 1 Clinical Study Of Rec 3565 A Selective Malt1 Inhibitor For Relapsed Or Refractory B Cell Lymphomas